Protocol: ATI-501-AUAT-201 Aclaris Therapeutics, Inc. CLINICAL STUDY PROTOCOL A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-501 Oral Suspension Compared to Placebo in Adult Subjects with Alopecia Areata, Alopecia Universalis or Alopecia Totalis Amendment 4 Compound: ATI-501 US IND Number: 129, 539 Protocol Number: ATI-501-AUAT-201 Phase: 2 Sponsor Medical Monitor Aclaris Therapeutics, Inc. Jeffrey Sugarman, MD, PhD 640 Lee Road Telephone: 707-545-4537 Suite 200 Facsimile: 707-545-6723 Wayne, PA 19087
[email protected] Telephone: 484-324-7933 Facsimile: 484-320-2344 Study Contact Safety Contact: Sue Moran, RN, MSN Deborah S. Kelly, M.D. Sr. Director, Clinical Development Senior Medical Director, Safety, PV & Risk Aclaris Therapeutics, Inc. Management 640 Lee Road Aclaris Therapeutics, Inc. Suite 200 640 Lee Rd Wayne, PA 19087 Suite 200 Telephone: 484-329-2129 Wayne, PA 19087 Cell: 484-999-7492 Telephone: 484-540-2262 E-mail:
[email protected] Cell: 484-280-2262 Email:
[email protected] ProPharma email:
[email protected] This document is a privileged and confidential communication of Aclaris Therapeutics, Inc. Acceptance of this document constitutes an agreement by the recipient that no unpublished information contained herein will be used, published or disclosed without prior written approval from Aclaris Therapeutics, Inc. Date: 09APR2019, Version 5.0 Page 1 of 90 CONFIDENTAL Protocol: ATI-501-AUAT-201 Aclaris Therapeutics, Inc. INVESTIGATOR’S AGREEMENT I have received and read the Investigator’s Brochure for ATI-501. I have read the ATI-501- AUAT-201 protocol and agree to conduct the study as outlined.